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Abstract 
 
Today, in conditions of strict quarantine, when it is not always possible to carry out surgery in cats, some methods 
of emergency drug contraception can be used. Over the years, many contraceptive medications have been devel-
oped for companion animals, but many secondary adverse effects have limited their use. However, in all species, 
the secondary adverse effects of progesterone-type drugs limit their use and vary depending on when treatment is 
given in relationship to the stage of the estrous cycle. An ideal non-surgical sterilant would be safe, effective, 
permanent, administered as a single injection and capable of being manufactured inexpensively. Contraceptives 
are used for cats, as a method of renewable fertility over time for breeding animals, as a method of suppressing 
sexual function for animals at risk for surgery, and to prevent over populations in stray cats. The use of non-
surgical, safe and effective methods of suppression of sexual function in cats eliminates traumatization, anesthesia 
and complicated postoperative period in animals, which in some cases are impossible in the state of health, etc. 
The most common and affordable method of medical contraception is progestins, such as megestrol acetate, 
medroxyprogesterone acetate, proligestone (used orally or as a depot injection). These drugs are effective in inhib-
iting sexual function. Contraceptives for felids are available as implants, depot injections, and pills or liquid for 
oral administration, powder for mixing with food, or as vaccines. Regimens may differ according to the timing of 
first treatment, whether coinciding with the active reproductive period, preceding this period, or during anestrus. 
Ideally, the treatment regimen is initiated during anestrus to minimize the dose needed for reproductive suppres-
sion and to avert exposure to endogenous steroids that can cause lesions in reproductive organs. 
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1. Introduction 
 
For many years, surgical castration has been the only re-
liable and permanent method of contraception in small ani-
mals. However, in many countries, discussion and even 
controversy surround the benefits and risks associated with 
these procedures (Reichler, 2009).  
Over the years, many contraceptive medications have 
been developed. In approximately 1960, with the availability 
of orally active and increasingly more effective progestins in 
humans, efforts began to control reproduction in dogs and 
cats. Many types of progestins, oral or injectable, have been 
used for estrous control in small animals. However, in all 
species, the secondary adverse effects of progesterone-type 
drugs limit their use and vary depending on when treatment 
is given in relationship to the stage of the estrous cycle. An 
ideal non-surgical sterilant would be safe, effective, perma-
nent, administered as a single injection and capable of being 
manufactured inexpensively (Struthers, 2012). 
Contraceptives are used for cats, as a method of renewa-
ble fertility over time for breeding animals, as a method of 
suppressing sexual function for animals at risk for surgery, 
and to prevent over populations in stray cats 
The use of non-surgical, safe and effective methods of 
suppression of sexual function in cats eliminates traumatiza-
tion, anesthesia and complicated postoperative period in 
animals, which in some cases are impossible in the state of 
health, etc. 
The most common and affordable method of medical 
contraception is progestins, such as megestrol acetate, 
medroxyprogesterone acetate, proligestone (used orally or as 
a depot injection). These drugs are effective in inhibiting 
sexual function. 
However, long-term use violation of dosage and use in 
animals with pathology of the reproductive system and 
mammary gland is may associated with endometrial hyper-
plasia, endometrial cancer, and mammary cancer. There are 
methods and protocols for the safe use of progestins for cats, 
in which the risk of side effects is reduced. 
Contraception in its broadest sense is preventing the 
birth of offspring while maintaining the potential for fertili-
ty. Contraception can be achieved by preventing gamete 
formation, conception, or implantation, as well as by dis-
rupting pregnancy (causing resorption or abortion). Contra-
ceptives are more widely used in females where the intri-
cately orchestrated events leading to oogenesis, ovulation, 
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gamete transport and implantation are more easily disrupted 
than is spermatogenesis in the male. Reproductive cyclicity 
and gametogenesis in both sexes can be disrupted by admin-
istrating exogenous hormones that interfere with the normal 
hypothalamic/pituitary/gonadal axis, prevent hormonal syn-
thesis or release, or interfere with endocrine activity at the 
tissue level. Spermatogenesis also can be directed arrested 
by some chemicals. Fertilization can be averted by physical-
ly blocking the reproductive tract, altering the uterine milieu 
necessary for sperm movement, or interfering with sperm–
egg binding necessary for fertilization (Munson, 2006). 
Contraceptives for felids are available as implants, depot 
injections, pills or liquid for oral administration, powder for 
mixing with food, or as vaccines. Regimens may differ ac-
cording to the timing of first treatment, whether coinciding 
with the active reproductive period, preceding this period, or 
during anestrus. Ideally, the treatment regimen is initiated 
during anestrus to minimize the dose needed for reproduc-
tive suppression and to avert exposure to endogenous ster-
oids that can cause lesions in reproductive organs (Wildt et 
al., 1998). 
Progestins 
Megestrol acetate, a synthetic progestin, is a tasteless, 
odorless crystalline powder. Megestrol acetate is rapidly 
metabolized when given orally (Plumb, 2002). It stops ovu-
lation and acts on LH and FSH production. Megestrol ace-
tate is highly patented; it is 5 times stronger than natural 
progesterone.  
Proposed mechanisms of megestrol acetate action in-
clude:  
1. negative feedback on the hypothalamus and pituitary 
gland leading to suppression of GnRH, FSH, or LH secre-
tion and failure of folliculogenesis and/or ovulation;  
2. altered motility of the tubular tract causing failed oo-
cyte transport and fertilization  
3. altered receptivity of the endometrium resulting in 
implantation failure (Munson, 2006).  
Megestrol acetate (MA) is considered to be one of the 
older generation of drugs with high gestagenic and antigon-
adotropic activity but poor anti-estrogenic effects. Megestrol 
acetate suppressed follicular development or ovulation, 
suggesting that hypothalamic and pituitary suppression is 
not the means by which these agents effect contraception. In 
general, progestins promote endometrial growth and secre-
tion, as well as smooth muscle relaxation in the uterus 
(Hafez et al., 2000). Therefore, altered uterine motility and 
endometrial receptivity are the likely mechanisms for pro-
gestin-induced contraception. 
All progestin drugs that used for cats have 
pharmacological form of pills or drops and injection form. 
Its cheap costs and available in veterinarian pharmacy and 
zoo-shop. Specific example of such drugs that are most 
popular commercially available in Ukraine listed in Table 1. 
 
Table 1  
Most popular and commercially available in Ukraine progestin contraceptives 
 
Contraceptive Brand name Manufacture Method of delivery 
Megestrol acetate 
Kontric 
Nonoestrone 
Pillcane-5 
EKS-5 
Sexinon 
Sexanet 
Farmatone 
Prima-Vet 
CEVA 
AVZ 
O.L.KAR 
Brovafarma 
Oral pills 
Oral pills 
Oral sugar cubes 
Oral drops 
Oral pills/drops 
Oral/pills/drops 
Medroxyprogesterone 
acetate 
Proveravet 
Medropet 
Depogestone 
Vetsyntes 
GiGi 
Biowet-Pulawy 
Oral pills 
Oral pills 
Injection depot 
Proligetone Covinan Intervet Injection depot 
 
In all instruction for megestrol acetate drugs was written 
that its highly effective at suppressing estrus in queens when 
given at a dose of 5 mg/cat orally for 5 days and then once 
weekly. 
Nevertheless, after numerous studies, scientists have 
suggested other dosages megestrol acetate to reduce the 
likelihood of side effects. One of the principles of using 
megestrol acetate: “Low dosing for individual cat. One cat. 
One dose. One week” (Romagnoli, 2015). 
 
 Fig. 1. Scheme of megestrol acetate dosage and side effects in cats 
 
Treatment regimens differ depending on whether treat-
ment is initiated during anestrus, estrus, or diestrus. In the 
anestrous domestic cat, an initial dose of 2.5–5 mg/day for 
3–5 days has been recommended, followed by 2.5–
5 mg/week (Oen, 1977). Cats in estrus may require a higher 
dose (5 mg/day until estrus stops, then 2.5–5 mg/week, per 
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os) (Plumb, 2002). The recommended dose for diestrous 
cats is 2.5 mg/day per os (Romagnoli, 2015). Treated cats 
should be separated from adult males for at least 1 week to 
assure efficacy. Recommended duration of treatment ranges 
from 2 to18 months, followed by a period of normal estrous 
cycles before treatment is repeated (Romatowski, 1989). 
Most MA-treated cats return to estrus within a few days. 
Reported side effects of prolonged megestrol acetate 
treatment in cats included: increased appetite leading to 
weight gain; lethargy or restlessness (Burke, 1982); marked 
mammary stimulation with hyperplastic and/or neoplastic 
changes; clinical and pathologic changes typical of diabetes 
mellitus (Kutzler & Wood, 2006). 
Also was proved experimentally scheme when MA was 
given in complex with homeopathic drugs such “Ovaryovit” 
and “Mastometrin” (5 mg/per cat orally and IM injection 
1ml/per cat “Ovaryovit” and “Mastometrin” 3 times per 
week during 6 weeks. During these study only 19 % side 
effects on reproductive organs and mammary gland were 
registered (Vasetska & Stefanyk, 2018). 
Medroxyprogesterone acetate (MPA) belongs to the old 
generation of contraceptive agents. It is characterized by 
high antigonadotropic and gestagenic activity, but shows a 
relatively small antiestrogenic effect (Evans & Sutton, 
1989). It is slowly metabolised in the liver. After a single 
administration during the proestrus MPA blocks the estrous 
cycle for on average 6 months. However, a lack of heat was 
also described in some queens up to 26 months after appli-
cation. For this reason, MPA administered parenterally 
should not be used in valuable breeding animals. When 
administered orally, this compound is effective for suppres-
sion of heat during proestrus as well as for temporary post-
ponement of heat (Max & Jurka, 2006). 
However, proliferations of endometrium and mammary 
glands, leading to developments of infertility and mammary 
hyperplasia are the adverse effects of the exogenous proges-
tins (Chatdarong et al., 2005). A single administration of 
depot MPA (at least 10 mg/kg) has shown to develop fi-
broadenomatous mammary hyperplasia in the cats (Loretti et 
al., 2005). However, the hyperplasia of the mammary tissue 
can be subsided after treatment with aglepristone, a proges-
terone receptor blocker (10 mg/kg twice at an interval of 24 
hours) (Romagnoli & Concannon, 2003). Also proposed 
new effective scheme of MPA 5 mg/cat once per month 
when queen has no sign of estrus, during 20 months. During 
treatment in experimental study side effects was in 17 % of 
cats and this side effects were reversible did not require 
surgery (Vasetska & Mass, 2018). 
 
Table 2 
Drug regimens for various progestins in cats 
 
Component Treatment References 
Progestin    
Megestrol acetate 2.5–5 mg/day for 3–5 days 
2.5–5 mg/week 
5 mg/day until estrus stops than  
2.5–5 mg/week  
diestrous cats is 2.5 mg/day  
5 mg/cat once per month when queen has no 
sign of estrus, during 20 months 
Oen E. O., 1977 
 
Plumb D. C., 2002 
 
Romagnoli S., 2015 
Vasetska A., Stefanyk V., 2018 
Medroxyprogesterone  
acetate 
10 mg/kg twice at an interval of 24 hours 
5 mg/cat once per month when queen has no 
sign of estrus, during 20 months 
Romagnoli S., Concannon P. W., 2003 
Vasetska A. I., Mass A. O., 2018 
 
Proligestone (14a, 17α-propylidene-dioxy progesterone) 
is a unique progestin with weaker progestational activity 
than other synthetic progestins (Plumb, 2002). Proligestone 
is marketed in Europe and Ukraine (Covinan, Intervet) as an 
injectable canine and feline contraceptive. The manufacturer 
claims that it is safe to use for prevention, delay or suppres-
sion of estrus when given to female dogs at an initial dose of 
10–30 mg/kg SQ, with repeated administration 3 and 
7 months later. It can also be given to female cats (1 ml 
subcutaneously), causing estrus suppression for about 6.5 
months. In clinical trials, this regimen did not promote de-
velopment of uterine disease or mammary tumors (Kutzler 
& Wood, 2006). 
The use of exogenous progestins however is associated 
with several important side effects (Max & Jurka, 2006). 
These are most frequently observed in the uterus, such as 
endometrial cystic degeneration, also referred to as CEH – 
cystic endometrial hyperplasia (Kim & Kim, 2005; Keskin 
et al., 2009). While estrogens stimulate progesterone recep-
tors in the endometrium, progesterone and synthetic proges-
tins stimulate uterine glands to secretion, causing hyperplas-
ia and hypertrophy, and consequently the formation of cysts 
of various sizes, which often is accompanied by infiltration 
of leukocytes. Prolonged secretory activity in combination 
with infection of the uterine cavity (especially in immuno-
compromised animals), may lead to the development of 
endometritis/pyometra complex. Furthermore, in dogs and 
cats mammary tumors, hyperglycemia and acromegaly were 
observed after repeated progestin administrations  
(Fagerstone et al., 2010). 
Progestins can stimulate local secretion of growth hor-
mone by the mammary glands, inter alia, via insulin-like 
growth factor IGF-1, which induces proliferative processes 
(Conneely et al., 2003). One of them is feline fibroadenoma-
tosis, the rapid, but not malignant, proliferation of cells in 
the ducts and stroma of the mammary glands which is con-
sidered to be hyperplastic/dysplastic changes. The condition 
may be a result of natural progesteronic activity and some-
times arises in cats treated with progestins, especially long-
acting formulations (Jurka & Max, 2009). Other possible 
side effects are adrenal dysfunction, hepatitis, developmen-
tal disorders, withholding of labor, behavioral changes and 
local skin alterations. Simultaneously with a decrease in the 
concentration of the administered progestinand the increase 
in prolactin secretion, signs of pseudopregnancy may be 
observed (Cathey & Memon, 2010). 
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2. Conclusions 
 
However, gonadectomy remains the procedure of choice 
for permanent sterilization of domestic cats. However, no 
single method of reproduction control will be a panacea for 
the suppression reproductive function and contraception 
problem in cats. Commercial development of products for 
hormonal down-regulation with exogenous steroid hor-
mones to provide nonsurgical alternatives for contraception 
and sterilization. 
Undoubtedly, each progestogen has its own side effects. 
Nevertheless, it is possible to avoid many side effects with 
the proper use of these medications. Under quarantine, non-
surgical methods of contraception can become an alternative 
to surgery. 
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